Compare · BNTX vs TWST
BNTX vs TWST
Side-by-side comparison of BioNTech SE (BNTX) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $22.84B, about 4.2x TWST ($5.45B).
- Over the past year, BNTX is down 11.9% and TWST is up 148.0% - TWST leads by 159.9 points.
- TWST has been more active in the news (11 items in the past 4 weeks vs 3 for BNTX).
- BNTX has more recent analyst coverage (25 ratings vs 14 for TWST).
- Company
- BioNTech SE
- Twist Bioscience Corporation
- Price
- $90.86-1.41%
- $87.53+5.58%
- Market cap
- $22.84B
- $5.45B
- 1M return
- +3.39%
- +76.72%
- 1Y return
- -11.85%
- +148.00%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2018
- News (4w)
- 3
- 11
- Recent ratings
- 25
- 14
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- The Multi-Billion-Dollar Search for Better Glioblastoma Treatments
- SEC Form 6-K filed by BioNTech SE
- Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
- BioNTech upgraded by UBS with a new price target
- Bernstein initiated coverage on BioNTech with a new price target
- SEC Form 6-K filed by BioNTech SE
- BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
- SEC Form 6-K filed by BioNTech SE
- BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
Latest TWST
- SEC Form S-3ASR filed by Twist Bioscience Corporation
- SVP of Human Resources Green Paula exercised 26,137 shares at a strike of $23.33 and sold $2,134,488 worth of shares (26,137 units at $81.67) (SEC Form 4)
- Canaccord Genuity initiated coverage on Twist Bioscience with a new price target
- Officer Cho Dennis sold $28,077 worth of shares (402 units at $69.84), decreasing direct ownership by 0.33% to 119,692 units (SEC Form 4) (tax liability)
- SVP of Human Resources Green Paula sold $61,742 worth of shares (884 units at $69.84), decreasing direct ownership by 0.73% to 120,705 units (SEC Form 4) to cover taxes
- Chief Executive Officer Leproust Emily M. sold $158,197 worth of shares (2,265 units at $69.84), decreasing direct ownership by 0.27% to 844,607 units (SEC Form 4) (for withholding tax)
- Chief Accounting Officer Werner Robert F. sold $94,046 worth of shares (1,359 units at $69.20) and gifted 500 shares, decreasing direct ownership by 4% to 46,327 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Laponis Adam sold $280,000 worth of shares (4,000 units at $70.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 112,675 units (SEC Form 4)
- Officer Cho Dennis sold $990,799 worth of shares (14,205 units at $69.75) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 120,094 units (SEC Form 4)
- Director Starovasnik Melissa A. sold $170,000 worth of shares (2,500 units at $68.00) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 22,222 units (SEC Form 4)